The bank holiday turned out to be a hot one, not least in the takeover arena. First, Shire Pharmaceutical accepted a £46 billion offer from Takeda of Japan — though the stock market did not seem wholly convinced that the deal will proceed. If it does, should we care?
Shire is a FTSE100 company that began in the UK and ended up stateless.
Already a subscriber? Log in
As the US decides, so can you
Subscribe today and get a $50 Amazon gift card if you correctly predict the next US president.
- Unlimited access to spectator.com.au
- The weekly edition on the Spectator Australia app
- Spectator podcasts and newsletters
- Full access to spectator.co.uk
Or
Unlock this article
You might disagree with half of it, but you’ll enjoy reading all of it. Try your first month for free, then just $2 a week for the remainder of your first year.
Comments
As the US decides, so can you
Subscribe today and get a $50 Amazon gift card if you correctly predict the next US president.
SUBSCRIBE AND ENTERAlready a subscriber? Log in